# A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct05852691/  
OnCo record `nct05852691` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in triple-negative breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT05852691 by Hoffmann-La Roche, with 83 participants enrolled, started 2023-07-18 and due to reach its primary completion in 2026-10-19. Interventions recorded: Tobemstomig, Pembrolizumab and Nab-Paclitaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05852691
- Phase: 2
- Setting: A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
- Sponsor: Hoffmann-La Roche
- Enrolled: 83

## Sources

- ClinicalTrials.gov NCT05852691: https://clinicaltrials.gov/study/NCT05852691

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct05852691.json